Osimertinib-Bevacizumab Effects on Progression-Free Survival in Patients With Metastatic EGFR-Mutant Lung Cancers

This interventional clinical trial examines the safety and tolerability of osimertinib and bevacizumab combination treatment and assesses the 12-month progression-free survival of the combination in patients with metastatic EGFR-mutant lung cancers.

Read the full article here

Related Articles